EP Patent

EP3437651A1 — Peptides for treatment and prevention of nonalcoholic fatty liver disease

Assigned to Institut National de la Sante et de la Recherche Medicale INSERM · Expires 2019-02-06 · 7y expired

What this patent protects

The present invention relates to peptides for the treatment or prevention of nonalcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), hepatic steatosis (fatty liver), liver fibrosis, liver inflammation, cirrhosis, or hepato…

USPTO Abstract

The present invention relates to peptides for the treatment or prevention of nonalcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), hepatic steatosis (fatty liver), liver fibrosis, liver inflammation, cirrhosis, or hepatocellular carcinoma.

Drugs covered by this patent

Patent Metadata

Patent number
EP3437651A1
Jurisdiction
EP
Classification
—
Expires
2019-02-06
Drug substance claim
No
Drug product claim
No
Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.